Hikma Pharmaceuticals PLC

HIK

Equity

ISIN GB00B0LCW083 / Valor 2324471

LSE London Stock Exchange, SETS (2026-09-08)

GBP 15.96-0.25%

Hikma Pharmaceuticals PLC
UMushroom community rating:

3.14 3 votes No rating yet

NegativeNeutralPositive

About company

Hikma Pharmaceuticals PLC is a London‑listed pharmaceutical company, founded in Jordan and headquartered in London, that develops, manufactures and commercialises a broad range of branded and generic medicines across the United States, the Middle East & North Africa and Europe. Its core operations cover three main areas—injectable medicines (including sterile hospital injectables), generic oral medicines and branded generics for regional markets—supplied through its own manufacturing sites and commercial networks to hospitals, wholesalers and retail pharmacies. The company combines in‑house development and manufacturing with licensing and partnerships to bring off‑patent and complex generic products to market, with a particular emphasis on injectable and hospital-use therapies.

Summarized from source with an LLMView SourceSector: Healthcare

Headline numbers

Core revenue $3,349m (+6% constant currency), core operating profit $741m (+3% cc) and core EBITDA $853m (+4%); reported revenue $3,349m (+7% reported) and reported operating profit $542m (down 11% driven by a legal settlement).

Profitability & EPS

Core profit attributable to shareholders $503m (core basic EPS 228 cents); reported profit $402m (reported basic EPS 182 cents). Core operating margin was 22.1% (reported operating margin 16.2%).

Segment performance

Injectables: core revenue $1,423m (+7% cc) with core margin 31.0% (down from 35.3%). Branded: core revenue $849m (+10% cc) and core margin 26.4% (improving). Hikma Rx: core revenue $1,037m (broadly flat) with core margin 17.3%.

Cashflow, debt & balance sheet

Operating cash flow $436m (2024: $564m) — excluding $186m one‑off legal settlements cashflow rose ~10%; net debt $1,387m and leverage ~1.6x net debt to core EBITDA. S&P and Fitch upgraded Hikma to BBB (stable).

Capital returns & 2026 guidance

Total dividend increased to 84 cents per share (+5%) and a $250m share buyback was announced to be executed in 2026. 2026 outlook: Group revenue +2% to +4% (cc) and Group core operating profit $720m–$770m.

One‑off items & drivers

Reported results were impacted by a legal settlement related to sodium oxybate and other adjustments; finance income included a $72m item from royalty/contingent consideration adjustments. Management plans increased investment in Injectables to address margin pressures.

Leadership changes

Said Darwazah will focus exclusively as CEO (stepping down as Executive Chairman); Victoria Hull appointed Chair and Douglas Hurt becomes SID. New Deputy CEO roles created (Mazen Darwazah for MENA; Khalid Nabilsi for North America & Europe) and a CFO search is underway with Areb Kurdi as Acting CFO.

Summarized from source with an LLMView Source

Key figures

-6.06%1Y

-23.5%3Y

-37.0%5Y

Performance

36.1%1Y

28.2%3Y

28.7%5Y

Volatility